AGENAgenus Inc.
Is the business good?
Margins widening. That is the only one of 4 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Operating margin has widened over the past few years, the business is getting more profitable per dollar of sales.
Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.
How good a business is AGEN?
Agenus Inc. keeps 27% of every revenue dollar as operating profit, against −82% for the median Biotechnology name.
Operating margin · Biotechnology median −82% · 12 months to Q2 2026
- Share count, year on year
- +47%
Share count, year on year · shareholders own a smaller slice than a year ago
- R&D as % of revenue
- 43%
R&D as % of revenue
- Gross margin
- 100%
Gross margin
| Year | Operating margin |
|---|---|
| FY2020 | −133% |
| FY2021 | 8.7% |
| FY2022 | −183% |
| FY2023 | −102% |
| FY2024 | −116% |
| FY2025 | −18% |
Details›
- Gross margin12 months to Q2 2026
- 100%
- Operating margin12 months to Q2 2026
- 27%
- Net margin12 months to Q2 2026
- 69%
- Free cash flow margin
- −74%
- R&D as % of revenue
- 43%
- Revenue, trailing twelve months
- $133M
- Free cash flow, trailing twelve months
- −$99M
- Net income, trailing twelve months
- $92M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.
Customers and suppliers
Who buys from AGEN and who it buys from, as the companies report it.
- One collaboration partner95%
Share of revenue · FY2025 10-K
None disclosed.
A company has to disclose every customer behind 10% or more of its revenue. Each share comes from the latest annual report of the company that states it and shows on both companies’ pages; AGEN’s own figures are from its FY2025 10-K. Smaller customers and suppliers go unreported.